Menu
Curie Logo
Donate
  • Home

Clinical trials - page 6

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Lymphoma
    Saint-Cloud
    CA073-1020
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

    CLEMENTINE SARKOZY

  • Paris
    EUonQoL
    Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.

  • Lung cancer
    Paris
    HARMONi-3
    A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

    PAULINE DU RUSQUEC

  • ENT/Head and Neck Cancers
    Paris
    AV-299-23-301
    A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)

    EDITH BORCOMAN

  • Paris, Saint-Cloud
    PALLU
    A randomized comparative prospective multicenter study of the efficacy of a systematic referral to palliative care of patients who need for palliative care during an unscheduled visit in comprehensive anticancer centers.

    CAROLE BOULEUC-PARROT

  • Hématologie / cancers du sang
    Saint-Cloud
    CA073-1022
    Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced-Stage Follicular Lymphoma (GOLSEEK-2)"

    CLEMENTINE SARKOZY

  • Breast cancer
    Saint-Cloud
    CAAA603B12101 NeoB
    Phase Ib Dose Finding Study Assessing Safety and Activity;of [;177Lu]LuNeob in combination with ribocilcib and fulvestrant;in subjects with HR positive, HER2 negative breast cancer,;experiencing early relapse from (neo)adjuvant endocrine;therapy.

    CAPUCINE RICHARD

  • Paris
    MK3475-522 (Keynote-522)
    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    MARIE PAULE SABLIN

  • Breast cancer
    Paris
    PRETORIA
    PROSPECTIVE EVALUATION OF A PREDICTIVE TOXICITY TEST POST RADIOTHERAPY AFTER MASTECTOMY WITH IMMEDIATE IMPLANT RECONSTRUCTION.

    YOULIA KIROVA

  • Childhood and adolescent cancers
    Paris
    I3Y-MC-JPEH
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    ISABELLE AERTS GAJDOS

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    SURVEILLE HPV
    National, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.

    JOEY MARTIN

  • Sarcomas
    Paris
    TRUST
    Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

    CLEMENT BONNET

  • Paris
    TUMOSS
    Comparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds (TUMOSS)

  • Hématologie / cancers du sang
    Saint-Cloud
    MO44869_GLOASIS
    https://clinicaltrials.gov/study/NCT06558604?term=gloasis&rank=1

    CLEMENTINE SARKOZY

  • Saint-Cloud
    CANTO BIS
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

    FLORENCE LEREBOURS

  • Digestive cancers
    Saint-Cloud
    CL1-95029-002
    Open-label, non-randomized, Phase 1b/2 trial investigating the;safety, tolerability, and antitumor activity of S095029 (anti-;NKG2A antibody) as a part of combination therapy in participants;with locally advanced and unresectable or metastatic MSIH/;dMMR gastroesophageal junction /gastric cancer

  • Sarcomas
    Paris
    TANGENT (SNX-301-020)
    A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

    SOPHIE PIPERNO-NEUMANN

  • Breast cancer
    Paris, Saint-Cloud
    Treat ctDNA
    Elacestrant for Treating ER+/·HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

    FRANCOIS-CLEMENT BIDARD, ETIENNE BRAIN

  • Breast cancer
    Paris, Saint-Cloud
    CAPPA
    Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

    DELPHINE LOIRAT

  • Lung cancer
    Paris
    R2810-ONC-2268
    A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075

    NICOLAS GIRARD

  • Tumeurs du système nerveux central
    Paris, Saint-Cloud
    COG-PROTON-01
    Long-term cognitive and functional impact of proton-therapy or modern fractionated radiotherapy in cavernous sinus meningioma: An open-label randomized 1:1 phase III study

    EMMANUEL JOUGLAR, MAXIME LOO

  • ENT/Head and Neck Cancers
    Paris
    MCLA-158-CL03/LiGeR-HN1
    A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

    CHRISTOPHE LE TOURNEAU

  • Paris
    CP-START 001
    Open-label, First-in-Human, Phase 1/2 Study with Dose Escalation and Expansion of STAR0602, a Bifunctional Antibody Fusion Targeting Selective T Cell Receptors (TCR), in Patients with Unresectable, Locally Advanced, or Metastatic Antigen-Rich Solid Tumors (START-001).

    CHRISTOPHE LE TOURNEAU

  • Saint-Cloud
    D7407C00001- SOUNDTRACK-E
    A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E).

    CLEMENTINE SARKOZY

  • Breast cancer
    Paris, Saint-Cloud
    HEROES
    De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

    DIANA BELLO ROUFAI

  • Breast cancer
    Paris, Saint-Cloud
    CAMBRIA-2
    CAMBRIA-2: A Phase III, Randomised, Open-label Study to Evaluate the Efficacy and Safety of Camizestrant (AZD9833), a Next Generation Oral Selective Estrogen Receptor Degrader (ngSERD), Compared with Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment in Patients with Estrogen Receptor-positive, HER2-negative Early Breast Cancer at Medium to High or High Risk of Recurrence, Who Have Completed Definitive Locoregional Therapy and Have No Evidence of Disease.

    PAUL-HENRI COTTU, FRANCOIS-CLEMENT BIDARD

  • Breast cancer
    Paris
    BGB-43395-101
    Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.

    MARIE PAULE SABLIN

  • Cancers gynécologiques
    Saint-Cloud
    E7386-J081-102_(PENT-02)
    An Open-Label Study of E7386 in Combination With Other;Anticancer Drug(s) in Subjects With Solid Tumors.

    DIANA BELLO ROUFAI

  • Paris
    GSK 219451 - POPSTAR
    Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).

    AMAURY LERUSTE

  • Saint-Cloud
    MK 2140-010
    A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).

    CLEMENTINE SARKOZY

<
1 ...67
>